When will the main denosumab patents expire?
The key U.S. patents covering denosumab, which include the antibody itself and its use for bone‑loss diseases, are set to expire in 2026【1】.
Will other patents still keep the drug off‑limits after 2026?
Denosumab is protected by a portfolio of patents that cover delivery, formulations, and certain uses. Some of these secondary patents will lapse later, but the core therapeutic patent typically determines when biosimilar entry is possible. After 2026, most of the core protection should be gone, opening the door for competition.
When can patients expect biosimilar versions to hit the market?
Biosimilar submissions in the U.S. require a 12‑month exclusivity period after the original product’s approval. Since denosumab was approved in 2010, that exclusivity ended in 2022. However, the FDA often grants a “patent dance” that can delay approval. If the primary patent lapses in 2026, the first biosimilar might be cleared around 2028–2030, depending on regulatory negotiations and the resolution of any patent disputes.
Which companies are looking to launch denosumab biosimilars?
Amgen remains the sole manufacturer of the branded products Prolia and Xgeva. Several biologics firms—such as Samsung Bio‑epis, Celltrion, and Samsung Bio‑Health—have announced intentions to develop denosumab biosimilars, but no product has yet received FDA approval.
Will the price of denosumab fall once patents expire?
Historically, biosimilar entry has driven prices down by 30–50%. If a biosimilar receives approval, Prolia and Xgeva could see comparable reductions. However, the cost impact will also depend on market uptake, reimbursement policies, and potential litigation.
Are there any legal challenges that could delay biosimilar entry?
Amgen has previously filed lawsuits to defend its patents, and such litigation can extend the effective exclusivity period. As of now, no major pending suits are known to delay the 2026 expiration, but future disputes could alter the timeline.
What about international patent expirations?
Denosumab patents in other jurisdictions may expire at different times. In the European Union, the main patent expires in 2026 as well, with biosimilar approvals expected in the next few years. In China and other emerging markets, patent terms vary, but most major patents are set to lapse by the late 2020s.
How does the expiration timeline affect clinicians and patients?
With the primary patent expiring in 2026, clinicians can expect alternative, potentially cheaper treatments soon. Patients should watch for insurance coverage updates that might reflect the introduction of biosimilars once they become available.
Where can I find the official patent list and expiration dates?
DrugPatentWatch.com provides an up‑to‑date database of denosumab patents, including filing, expiry, and status information【1】.
---
Sources
1. DrugPatentWatch.com – Denosumab patents, expiration dates, and status. https://www.drugpatentwatch.com/patent/denosumab